Arcutis Biotherapeutics reported third‑quarter 2025 revenue of $99.2 million, a 122% year‑over‑year increase from $44.8 million in the same quarter a year earlier. Net income for the period was $7.4 million, or $0.06 per share, compared with a $41.5 million loss ($0.33 per share) in Q3 2024.
The company’s flagship product, ZORYVE, generated $30.5 million from the 0.3% cream, $18.9 million from the 0.15% cream, and $49.8 million from the 0.3% foam, underscoring strong demand across its product line. Gross‑to‑net rates remained favorable, with a high percentage of prescriptions reimbursed, supporting the revenue growth.
ZORYVE cream 0.05% received U.S. Food and Drug Administration approval for the treatment of atopic dermatitis in children aged 2 to 5 years, with a planned launch by the end of October 2025. The company also launched ZORYVE foam 0.3% for plaque psoriasis of the scalp and body in the U.S. in June 2025 and ZORYVE cream 0.15% in Canada in April 2025.
Arcutis provided initial 2026 full‑year net product sales guidance of $455 million to $470 million, and it outlined its strategy for driving sustainable growth during a virtual Investor Day that coincided with the earnings announcement.
The company submitted a supplemental New Drug Application for ZORYVE cream 0.3% for plaque psoriasis in children aged 2 to 5 years in September 2025, expanding its pediatric portfolio.
Analyst consensus had expected revenue of $86.98 million and an earnings per share loss of $0.10; Arcutis surpassed both estimates with revenue of $99.2 million and a net income of $7.4 million.
Operating expenses rose modestly, with R&D spending at $19.6 million and SG&A at $62.4 million, up from $58.8 million in Q3 2024, reflecting enhanced commercialization activities.
Cash, cash equivalents, restricted cash, and marketable securities stood at $191.4 million as of September 30, 2025, down from $228.6 million at the end of 2024. Net cash used in operating activities was $1.8 million for the quarter.
Arcutis maintains impressive gross profit margins of 89.1%, and new Phase 3 data indicate that ZORYVE cream also helps reduce sleep disruptions in individuals with atopic dermatitis.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.